Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Open-label, Study Evaluating the Efficacy and Safety of Nanvuranlat in Patients With Previously Treated Advanced Biliary Tract Cancer

NCT07265674 is registered in ClinicalTrials.gov with J-Pharma Co., Ltd. as lead sponsor.

NCT NCT07265674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07265674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Open-label, Study Evaluating the Efficacy and Safety of Nanvuranlat in Patients With Previously Treated Advanced Biliary Tract Cancer
Lead sponsor
J-Pharma Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
May 11, 2026
Completion date
October 31, 2027
Enrollment
480 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

advanced biliary tract cancer, biliary tract cancer (btc)